​

Illumina (ILMN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ILMN Stock Forecast

Illumina (ILMN) stock forecast, based on 50 Wall Street analysts, predicts a 12-month average price target of $252.73, with a high of $305.00 and a low of $155.00. This represents a -6.19% decline from the last price of $269.40.

$100 $150 $200 $250 $300 $350 High: $305 Avg: $252.73 Low: $155 Last Closed Price: $269.4

ILMN Stock Rating

Illumina stock's rating consensus is Buy, based on 50 Wall Street analysts. The breakdown includes 1 Strong Buy (2.00%), 26 Buy (52.00%), 17 Hold (34.00%), 6 Sell (12.00%), and 0 Strong Sell (0.00%).

Buy
Total 50 6 17 26 1 Strong Sell Sell Hold Buy Strong Buy

ILMN Price Target Upside V Benchmarks

TypeNameUpside
StockIllumina-6.19%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks1.69%

Price Target Trends

1M3M12M
# Anlaysts61338
Avg Price Target$280.83$247.38$182.42
Last Closing Price$269.40$269.40$269.40
Upside/Downside4.24%-8.17%-32.29%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 264762221
Sep, 264661320
Aug, 264751320
Jul, 264751320
Jun, 263751319
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 23, 2026Stephens$275.00$268.002.61%2.08%
Oct 19, 2026Canaccord Genuity$300.00$262.5414.27%11.36%
Oct 07, 2026Barclays$200.00$273.54-26.88%-25.76%
Oct 01, 2026Subbu NambiGuggenheim$305.00$270.8112.63%13.21%
Sep 29, 2026Leerink Partners$300.00$273.639.64%11.36%
Sep 28, 2026David WestenbergPiper Sandler$305.00$270.0012.96%13.21%
Sep 09, 2026UBS$260.00$211.0623.19%-3.49%
Sep 03, 2026Argus Research$235.00$213.2510.20%-12.77%
Aug 03, 2026Canaccord Genuity$205.00$205.10-0.05%-23.90%
Jul 31, 2026RBC Capital$230.00$199.1315.50%-14.63%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2026Cowen & Co.HoldHoldhold
Oct 07, 2026BarclaysUnderweightUnderweighthold
Oct 01, 2026GuggenheimBuyBuyhold
Sep 28, 2026Piper SandlerOverweightOverweighthold
Aug 05, 2026Deutsche BankHolddowngrade
Aug 03, 2026CitigroupSellSellhold
Jul 31, 2026RBC CapitalOutperformOutperformhold
Jul 31, 2026BernsteinMarket PerformMarket Performhold
Jul 31, 2026GuggenheimBuyBuyhold
Jul 31, 2026BarclaysUnderweightUnderweighthold

Financial Forecast

EPS Forecast

$-30 $-22 $-14 $-6 $2 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.08$-28.05$-7.35$-7.69$5.47---
Avg Forecast$5.56$2.23$0.73$4.12$4.44$5.15$5.85$6.61
High Forecast$5.65$2.29$0.87$4.13$4.58$6.35$7.43$6.67
Low Forecast$5.44$2.18$0.62$4.09$4.33$3.56$4.75$6.53
Surprise %-8.63%-1357.85%-1106.85%-286.65%23.20%---

Revenue Forecast

$4B $5B $5B $5B $5B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.53B$4.58B$4.50B$4.37B$4.34B---
Avg Forecast$4.45B$4.57B$4.46B$4.33B$4.44B$4.68B$4.98B$5.25B
High Forecast$4.51B$4.67B$4.49B$4.36B$4.47B$4.69B$4.99B$5.29B
Low Forecast$4.38B$4.49B$4.44B$4.32B$4.40B$4.67B$4.96B$5.20B
Surprise %1.66%0.24%0.88%0.92%-2.16%---

Net Income Forecast

$-5B $-3B $-2B $-900M $300M $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$762.00M$-4.40B$-1.16B$-1.22B$850.00M---
Avg Forecast$878.46M$554.35M$-1.16B$649.63M$704.41M$679.88M$841.27M$1.04B
High Forecast$892.13M$665.22M$-928.80M$652.79M$724.31M$1.00B$1.17B$1.05B
Low Forecast$860.23M$443.48M$-1.39B$646.47M$684.51M$562.33M$750.97M$1.03B
Surprise %-13.26%-894.45%--288.26%20.67%---

ILMN Forecast FAQ

Is Illumina stock a buy?

Illumina stock has a consensus rating of Buy, based on 50 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 26 Buy, 17 Hold, 6 Sell, and 0 Strong Sell, reflecting a consensus that Illumina is a favorable investment for most analysts.

What is Illumina's price target?

Illumina's price target, set by 50 Wall Street analysts, averages $252.73 over the next 12 months. The price target range spans from $155 at the low end to $305 at the high end, suggesting a potential -6.19% change from the previous closing price of $269.4.

How does Illumina stock forecast compare to its benchmarks?

Illumina's stock forecast shows a -6.19% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (1.69%).

What is the breakdown of analyst ratings for Illumina over the past three months?

  • October 2026: 19.05% Strong Buy, 33.33% Buy, 28.57% Hold, 9.52% Sell, 9.52% Strong Sell.
  • September 2026: 20.00% Strong Buy, 30.00% Buy, 30.00% Hold, 5.00% Sell, 15.00% Strong Sell.
  • August 2026: 20.00% Strong Buy, 35.00% Buy, 25.00% Hold, 5.00% Sell, 15.00% Strong Sell.

What is Illumina’s EPS forecast?

Illumina's average annual EPS forecast for its fiscal year ending in December 2026 is $5.15, marking a -5.85% decrease from the reported $5.47 in 2025. Estimates for the following years are $5.85 in 2027, and $6.61 in 2028.

What is Illumina’s revenue forecast?

Illumina's average annual revenue forecast for its fiscal year ending in December 2026 is $4.68B, reflecting a 7.82% increase from the reported $4.34B in 2025. The forecast for 2027 is $4.98B, and $5.25B for 2028.

What is Illumina’s net income forecast?

Illumina's net income forecast for the fiscal year ending in December 2026 stands at $679.88M, representing a -20.01% decrease from the reported $850M in 2025. Projections indicate $841.28M in 2027, and $1.04B in 2028.